FREE SHIPPING! on orders over $99*

Categories

Resources

0 $0.00
YOUR CART

SUPPORT

Expect shipping delays Sept 28-Oct 9 due to the Jewish high holidays. Order now to ensure your delivery.

  • US Name:

    Tarceva

  • Israeli Names:

    Tarceva

  • Active Ingredients:

    Erlotinib

  • Brand Manufacturer:

    Roche

  • Manufacturer Location:

    Switzerland

  • Click here to view Product Insert

Tarceva

Tarceva is prescribed as a primary treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) driven by common epidermal growth factor receptor (EGFR). It is also used in combination with gemcitabine for patients with advanced-stage pancreatic cancer.

Prescription Required
Tarceva
Brand
150mg
30 Tablets
$931.00
*Please note all prices are in US dollars

Tarceva (generic name: erlotinib) is a Tyrosine Kinase Inhibitor (TKI) monotherapy prescribed for the treatment of advanced non-small cell lung cancer (NSCLC) in patients whose tumors are driven by common epidermal growth factor receptor (EGFR) gene-activating mutations. EGFR is a protein that stimulates cell growth, and a mutation in the gene for EGFR can cause cancer. Comprehensive next-generation sequencing (NGS) tests are used to detect EGFR mutations. 

Tarceva in chemotherapy along with gemcitabine monotherapy (GEM) is also indicated for patients with advanced pancreatic cancer. GEM is recommended for patients with metastatic pancreatic cancer but its therapeutic effect is hampered by its rapid metabolism and drug resistance. Therefore, GEM-based combination therapy (gemcitabine plus Tarceva) is recommended because of the significant improvements in patient outcomes.

Precautions

Do not drink grapefruit juice or eat grapefruit. It is advisable to stop smoking before starting treatment with Tarceva.

Serious side effects

This medication has been prescribed because your healthcare provider has judged that the benefits are greater than the risk of side effects. Many people using this medication do not have serious side effects. 

In the treatment of NSCLC, Tarceva can cause serious side effects, including:

  • interstitial lung disease (ILD) with symptoms such as:
    • shortness of breath
    • cough
    • Fever
  • liver and kidney problems
  • gastrointestinal (GI) perforation
  • blistering and skin peeling
  • bleeding and blood clotting problems – tell your doctor if you are taking blood thinners, such as warfarin
  • serious or ongoing diarrhea, nausea, loss of appetite, or vomiting
  • eye problems (dry eyes, unusual eyelash growth, swelling of the cornea).

In any such event, call your healthcare provider or pharmacist as soon as possible.

Common side effects

Common side effects of Tarceva for treating NSCLC include:

  • diarrhea
  • weakness
  • rash
  • cough
  • shortness of breath
  • loss of appetite.

The common side effects of Tarceva in pancreatic cancer treatment include:

  • fatigue
  • rash
  • nausea
  • loss of appetite
  • diarrhea.

In any such cases, if the side effects persist for several days, or get worse, consult with your healthcare provider or pharmacist.

Adenocarcinoma subtype of non-small cell lung cancer (NSCLC) – otherwise known as epidermal growth factor receptor [EGFR]-positive lung cancer – represents about 10-15% of lung cancer cases in the United States, even amongst patients who have no smoking history. 

Patients with non-small cell lung cancer (NSCLC)  that have specific types of mutations of the EGFR gene are prescribed Tarceva as an EGFR targeted tyrosine kinase inhibitor (TKI). 

Tarceva is prescribed for patients with stage 4 lung cancer whose cancer has metastasized. Tarceva is not meant to be used at the same time as certain types of chemotherapy for NSCLC.

Tarceva is approved for advanced-stage pancreatic cancer (PCa), a highly aggressive lethal neoplasm, which is the fourth most common cause of cancer-related deaths in the United States. Tarceva in combination with gemcitabine is prescribed for patients with PCa whose cancer has spread, grown, or cannot be surgically removed and who have not previously received chemotherapy.

Gemcitabine monotherapy (GEM) is recommended for patients with metastatic disease or locally advanced disease, but its therapeutic effect is hampered by its rapid metabolism and drug resistance. As a result, GEM-based combination therapy (gemcitabine plus Tarceva ) is recommended for advanced PCa because of its significant effectiveness and safety.

Required

Send Your Prescription

Secure Payment

No Hidden Fees

Fast Shipping

Typically Under 7 days

Diabetes
detection

Five Signs of Diabetes

As many as 25% of people with type 2 diabetes don’t know they have it. Unlike type 1 diabetes, type 2 is a gradual process and often the signs and symptoms are so subtle that

Read More »

Are All Pharmacists Created Equally?

In my opinion, Australia has done more for pharmacists that any other country, where certain medications can be dispensed at the pharmacist’s discretion. For example, if a child comes in wheezing and short of breath, an Australian pharmacist can dispense a Ventolin Inhaler for asthma. In Israel, this would be illegal…

Read More »
Ask your doctor if HRT is right for you
Hormone Replacement Therapy

All About Hormone Replacement Therapy (HRT)

Hormone Replacement Therapy (HRT) is a treatment for relieving the effects of hormone changes during and after menopause. As the female body ages, hormone levels usually undergo a substantial change, around the mid-40s. As a

Read More »
buy myrbetriq online
50+

Myrbetriq for OAB

Overactive bladder (OAB) can be a very awkward and distressing problem, impacting your life in various ways and preventing you from doing what you enjoy for fear of embarrassment in social situations. We have had

Read More »
    Your Cart
    Your cart is empty
      cropped-IsraelPharm-logo-dark-final.png

      Before you go...

      Unlock

      $10 Off

      your first order